Opendata, web and dolomites

Biopsy X SIGNED

Endodrill® Model X - a new endoscopic biopsy instrument taking multiple cancer samples of varying depth in one single session

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Biopsy X" data sheet

The following table provides information about the project.

Coordinator
BIBBINSTRUMENTS AB 

Organization address
address: SCHEELEVAGEN 2
city: LUND
postcode: 223 63
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://www.bibbinstruments.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIBBINSTRUMENTS AB SE (LUND) coordinator 50˙000.00

Map

 Project objective

The overall objective of this 6-month Phase 1 project is to evolve the prototype of Biopsy X, the new reliable endoscopic biopsy instrument, taking multiple cancer samples of varying depth in one single session, to transform our initial business plan into a robust strategy for international commercialization and to prepare for a Phase 2 demonstration.

Our product is the missing link that will bring effective, fast and patient-friendly cancer diagnosis, setting up the new standard for this method. The EndoDrill® Model X is a unique combination of knowledge in mechanical engineering, physics and physiology. Research has been partially funded by Swedish R&D grants from Vinnova as well as from foundations (Sten K Jonsson Foundation, IKEA Foundation) and Lund University Innovation. Since 2017 the company is listed at AktieTorget stock market. Our ambition is to accelerate proper diagnosis progress so that 3 in 4 people will survive cancer within the next 20 years by making sure patients have access to the best, fastest, safe and characterized with ultra-high precision cancer diagnostic method, minimizing at the same time the level of discomfort.

BiBBInstruments AB is well-positioned to bring its innovation to the market. The product has been developed and validated by practitioners in close cooperation with Skåne University Hospital in Lund as well as by end-users. This has assured market proximity of all the R&D activities.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOPSY X" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOPSY X" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

NAAS (2019)

NaaS - Newsroom as a service

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More